Clinical Trials Logo

Esophagitis, Peptic clinical trials

View clinical trials related to Esophagitis, Peptic.

Filter by:

NCT ID: NCT05813561 Completed - Reflux Esophagitis Clinical Trials

The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis

Start date: December 30, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.

NCT ID: NCT05751694 Recruiting - Clinical trials for Gastroesophageal Reflux

Effectiveness of Visceral Manual Therapy in Bruxist Patients With Gastroesophageal Reflux

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Objective: check the effectiveness of visceral manual therapy on bruxist patients with gastroesophageal reflux. Design: Experimental, analytical, longitudinal, prospective, randomized, single-blind study with a blinded evaluator. Subjects: 68 subjects over 18 years old, with bruxism (diagnoses by a dentist) and gastroesophageal reflux (evidenced by the GERDQ test). Methods: Subjects will be randomized into 2 groups: an experimental group (EG) to which a visceral manual technique will be applied and a control group (CG) to which a placebo manual technique will be administered. Both groups will receive 2 interventions one week apart. The measurements will be made before and after the interventions, and a last measurement will be made one month after the last intervention. Therefore, the patient will visit the center 3 times.

NCT ID: NCT05695846 Recruiting - Clinical trials for Gastroesophageal Reflux

Diagnostic Tests in Supra-Esophageal Gastroesophageal Reflux Disease (SE-GERD)

SE-GERD
Start date: January 29, 2014
Phase: N/A
Study type: Interventional

After defining the manometric characteristics of UES incompetence associated with documented pharyngeal reflux, we will determine the reproducibility of manometric criteria for UES incompetence in prevention of pharyngeal reflux. We hypothesize that these criteria are comprised of either a single or constellation of manometric abnormalities. After determining the ability of externally applied cricoid cartilage pressure in preventing pharyngeal reflux, we further hypothesize that this approach will eliminate or reduce esophago-pharyngeal reflux by enhancing the UES pressure barrier. We anticipate there will be a close spatial correlation between the site of applied pressure and area of increased pressure within UES high pressure zone. Lastly, we will determine and characterize the effect of externally applied cricoid cartilage pressure on related functions such as belch and swallow, testing the hypothesis that these functions will not be impaired.

NCT ID: NCT05647668 Completed - Clinical trials for Gastroesophageal Reflux Disease

Laparoscopic Total vs Partial Fundoplication in Patients With Atypical Symptoms of Gastroesophageal Reflux Disease

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

One hundred and twenty patients with documented extraesophageal symptoms of gastroesophageal reflux disease were randomized to either undergo floppy Nissen (n= 60) or Toupet fundoplication (n= 60). Symptom scores of extraesophageal symotoms and quality of life were prospectively evaluated. Analysis of the treatment results showed a significant improvement of symptoms in both patient groups.Quality of life improved substantially at short- and long-term follow up in both groups and there were no statistical differences between the groups in this parameter.

NCT ID: NCT05604261 Not yet recruiting - Clinical trials for Gastroesophageal Reflux

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Start date: December 2022
Phase: Phase 2
Study type: Interventional

A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with Rabeprazole 20mg QD in patients with reflux esophagitis.

NCT ID: NCT05561179 Recruiting - Clinical trials for Gastroesophageal Reflux

Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease

Start date: September 30, 2022
Phase: N/A
Study type: Interventional

Gastroesophageal reflux disease (GERD) remains one of the most common pathologies seen among gastroenterologists, surgeons, and primary care physicians. The high prevalence of this condition lead to further investigations in its prevention, diagnosis, and management. For the treatment of this chronic condition, improvement in quality of life and long-term durability should be considered. Nowadays, proton pump inhibitors (PPIs) are considered the mainstay in the treatment of the patients with GERD; however, due to the increasing concern related to its safety in its long-term use and the over prescription of these drugs, new surgical and endoscopic interventions have emerged. A local treatment based on injections of hyaluronic acid, a natural nonimmunogenic mucosal defense, in the lower esophageal mucosa is a tentative treatment option for these patients. Based on this, the investigators pursue to assess the effects of hyaluronic acid in gastroesophageal reflux control.

NCT ID: NCT05556824 Recruiting - Clinical trials for Gastroesophageal Reflux

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Start date: March 3, 2023
Phase: Phase 2
Study type: Interventional

This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.

NCT ID: NCT05486169 Completed - Obesity Clinical Trials

Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy

SLEEFLUX
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The planned research is to analyze the occurrence of gastroesophageal reflux disease (GERD) before and after sleeve gastrectomy (SG). The study includes patients with BMI above 40 kg / m2 without symptoms of GERD before surgery and any pathological changes in gastroscopy. The day before the surgery, patients will be tested with impedance pH measurement. Thereafter, patients will undergo SG according to standard technique. As part of the follow-up 6 months after the surgery, the pH-measurement test with impedance again will be performed again for evaluation of the occurrence of GERD after surgery. It was planned to include 50 people in the study. The main aim of the study is to assess the frequency and quality of GERD in patients after SG.

NCT ID: NCT05452603 Recruiting - Clinical trials for Gastroesophageal Reflux

Usefulness of Wireless pH Monitoring in GERD Diagnosis

Start date: June 20, 2021
Phase:
Study type: Observational

Gastroesophageal reflux disease (GERD) is extremely common in our environment. Its diagnosis is complex. The Lyon Consensus defined, based on 24-hour pH monitoring, that an acid exposure time greater than 6% is definitely abnormal, less than 4% is normal, and between 4 and 6% is a gray area. The objective of this study is to describe the change in therapeutic behavior based on the result of prolonged pH recording performed with a 96-hour wireless pH measurement capsule in patients with GERD symptoms and an acid exposure time measured by impedanciometry/pH of 24 hours in the gray area. Also, describe the therapeutic outcomes.

NCT ID: NCT05422404 Not yet recruiting - Clinical trials for Gastroesophageal Reflux Disease

Anti-Reflux Mucosal Ablation(ARMA) and Anti-Reflux Mucosectomy(ARMS) in Gastroesophageal Reflux Disease

Start date: June 30, 2022
Phase: N/A
Study type: Interventional

According to the current published data and treatment mechanism, ARMS may led to more stenosis while ARMA may be less effective in long term follow-up. The changes of patient's life quality , UGI tract microbiota before and after different endoscopic treatment are also limited. So we want to conduct a exploratory prospective randomized controlled study in evaluating the mucosal healing, demand of PPI, life quality, emotion status, sleep quality, esophageal motility/ acid exposure and saliva microbiota between chronic GERD patients receiving ARMS and ARMA treatment.